Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI™ (brexpiprazole) for the treatment of schizophrenia in adults. REXULTI™ was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become commercially available in Canada this spring.
More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=206193#.WKgIRPKhHIU#ixzz4Z1aDGsNR